Table 1. Summary of patients undergoing EUS-GE with LLAMS.
| Overall (n = 31) | Malignant (n = 23) | Benign (n = 8) | |
| Age (years) | 61.35 ± 16.52 | 67.13 ± 10.77 | 44.75 ± 19.51 |
| Male | 54.84 % (17) | 56.52 % (13) | 50 % (4) |
| Etiology | Pancreatic 43.4 % (10) | Peptic stricture 50 % (4) | |
| Duodenal 17.39 % (4) | |||
| Metastatic 17.39 % (4) | Chronic pancreatitis 25 % (2) | ||
| Gallbladder 13.04 % (3) | |||
| Cholangiocarcinoma 4.35 % (1) | SMA syndrome 25 % (2) | ||
| Gastric 4.35 % (1) | |||
| Technical success | 100 % (31) | 100 % (23) | 100 % (8) |
| Mean follow-up (days) | 140.84 ± 160.41 | 88.35 ± 98.51 | 291.75 ± 211.40 |
| Median follow-up (days) | 70 | 54 | 290 |
| Clinical success | 93.55 % (29) | 91.30 % (21) | 100 % (8) |
| Adverse events | 3.23 % (1) | 0 % (0) | 12.5 %% (1) |
| Prior therapy (any) | 38.71 % (12) | 21.74 % (5) | 87.5 % (7) |
| Prior dilation | 16.13 % (5) | – | 62.5 % (5) |
| Prior SEMS | 16.13 % (5) | 17.39 % (4) | 12.5 % (1) |
| Prior dilation and SEMS | 6.45 % (2) | 4.35 % (1) | 12.5 % (1) |
EUS-GE, endoscopic ultrasound-guided gastroenterostomy; LLAMS, lumen apposing metal stent; SMA, superior mesenteric artery; SEMS, self-expanding metal stent